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ARTICLE
Phage-assisted continuous evolution of proteases
with altered substrate speciﬁcity
Michael S. Packer1,2,3, Holly A. Rees1,3 & David R. Liu1,3,4
Here we perform phage-assisted continuous evolution (PACE) of TEV protease, which
canonically cleaves ENLYFQS, to cleave a very different target sequence, HPLVGHM, that is
present in human IL-23. A protease emerging from ∼2500 generations of PACE contains 20
non-silent mutations, cleaves human IL-23 at the target peptide bond, and when pre-mixed
with IL-23 in primary cultures of murine splenocytes inhibits IL-23-mediated immune sig-
naling. We characterize the substrate speciﬁcity of this evolved enzyme, revealing shifted and
broadened speciﬁcity changes at the six positions in which the target amino acid sequence
differed. Mutational dissection and additional protease speciﬁcity proﬁling reveal the mole-
cular basis of some of these changes. This work establishes the capability of changing the
substrate speciﬁcity of a protease at many positions in a practical time scale and provides a
foundation for the development of custom proteases that catalytically alter or destroy target
proteins for biotechnological and therapeutic applications.
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Proteases are ubiquitous regulators of protein function in alldomains of life and represent approximately one percent ofknown protein sequences1. Substrate-speciﬁc proteases
have proven useful as research tools and as therapeutics that
supplement a natural protease deﬁciency to treat diseases such as
hemophilia, or that simply perform their native functions such as
the case of botulinum toxin, which cleaves SNARE proteins and
mediates beneﬁcial muscle paralysis in numerous therapeutic and
cosmetic applications2.
Researchers have engineered or evolved industrial proteases
with enhanced thermostability and solvent tolerance3, 4. Similarly,
a handful of therapeutic proteases have been engineered with
improved kinetics and prolonged activity5–7. The potential of
proteases to serve as a broadly useful platform for modulating the
activity of a protein of interest, however, is greatly limited by
the native substrate scope of known proteases. In contrast to the
highly successful generation of monoclonal antibodies with tailor-
made binding speciﬁcities8, the generation of proteases with novel
protein cleavage speciﬁcities has proven to be a major challenge.
For example, efforts to engineer trypsin variants that exhibit the
substrate speciﬁcity of the closely related protease chymotrypsin
were unsuccessful until researchers grafted the entire substrate-
binding pocket, multiple surface loops, and additional residues
from chymotrypsin9–12. This approach of replacing protease
residues with amino acids from related proteases to impart spe-
ciﬁcity features from the latter13, 14 has not provided proteases
with speciﬁcities not already known among natural proteases,
prompting researchers to instead turn to laboratory evolution to
generate proteases with novel speciﬁcities15–19.
Although most reports describe evolution of proteases that
cleave single mutant substrates, the evolution of a protease that
can degrade a target protein of interest will almost always require
changing substrate sequence speciﬁcity at more than one position
within a substrate motif. Simultaneous speciﬁcity changes at two
protease sub-sites has previously been accomplished in a stepwise
fashion requiring distinct rounds of evolution20. Continuous
evolution strategies, which require little or no researcher inter-
vention between generations21, therefore may be well-suited to
evolve over many generations proteases capable of cleaving a
target protein that differs substantially in sequence from the
preferred substrate of a wild-type protease. In phage-assisted
continuous evolution (PACE), a population of evolving selection
phage (SP) is continuously diluted in a ﬁxed-volume vessel (the
“lagoon”) by an incoming culture of host Escherichia coli22. The
SP is a modiﬁed phage genome in which the evolving gene of
interest has replaced gene III, a gene essential for phage infec-
tivity. If the evolving gene of interest possesses the desired activity
it will trigger expression of gene III from an accessory plasmid
(AP) in the host cell, thus producing infectious progeny encoding
active variants of the evolving gene. The mutation rate of the SP is
controlled using an arabinose-inducible mutagenesis plasmid
(MP) such as MP6, which encodes six mutagenic proteins that
disrupt DNA replication proofreading, base excision repair,
mismatch repair, and export of damaged nucleobases. Upon full
induction, this plasmid increases the mutation rate of the SP by
∼300,000 fold23. Because the rate of continuous dilution is slower
than phage replication but faster than E. coli replication, muta-
tions only accumulate in the SP.
Here we describe the use of PACE to continuously evolve TEV
protease, which natively cleaves the consensus substrate sequence
ENLYFQS, to cleave a target sequence, HPLVGHM, that differs at
six of seven positions from the consensus substrate and is present
in an exposed loop of the pro-inﬂammatory cytokine IL-23. After
constructing a pathway of evolutionary stepping stones and
performing ~2500 generations of evolution using PACE, a
resulting protease contains 20 amino acid substitutions, cleaves
human IL-23 at the intended target peptide bond, and blocks the
ability of IL-23 to stimulate IL-17 production in a murine sple-
nocyte assay. Together, these results establish a strategy for
generating proteases with speciﬁcities that have been altered at
several substrate positions in order to cleave a target protein of
interest.
Results
Choice of target substrate and protease. The biochemistry,
substrate speciﬁcity24, and structure25 of TEV protease have been
extensively studied. Previous directed evolution efforts yielded
TEV protease variants with altered speciﬁcity at any one of the
following positions: P6, P1, or P1ʹ15, 16, 18, 19. Based on these
studies and our own experiments in which we evolved TEV
protease variants that accept substitutions at P6 or P1, we created
an “evolvability” scoring matrix (Supplementary Table 1) that
assigns a difﬁculty score to each of the 20 possible amino acids at
each of the seven positions recognized by TEV protease. We used
this matrix to rank all possible heptapeptides within all human
extracellular proteins. From this ranking, we manually curated a
handful of disease-associated proteins in which the target peptide
sequences were predicted to be solvent exposed based on their
crystal structures (Supplementary Table 2).
The resulting candidate target sequences included HPLVGHM,
a peptide found in human IL-23. IL-23 is a pro-inﬂammatory
cytokine secreted by macrophages and dendritic cells in response
to pathogens and tissue damage, ultimately promoting an innate
immune response at the site of injury or infection. This immune
response is mediated by IL-23-dependent stabilization of Th17
cells, a class of T helper cells that produce pro-inﬂammatory
cytokines IL-17, IL-6, and TNFα26. Hyperactivity of this pathway
can lead to a variety of autoimmune disorders including psoriasis
and rheumatoid arthritis27. Monoclonal antibodies that neutralize
IL-23 are FDA-approved drugs for the treatment of psoriasis and
show promise in late-stage clinical trials for other autoimmune
disorders28. These studies suggest that a protease that catalyzes
IL-23 degradation may have anti-inﬂammatory activity.
The target peptide HPLVGHM differs from the TEV consensus
substrate sequence, ENLYFQS, at six of seven positions. Two of
these substitutions are predicted to not substantially impact TEV
protease activity due to its low speciﬁcity at positions P5 and P1ʹ,
while the other four substitutions occur at positions that are
known to be crucial speciﬁcity determinants of wild-type TEV
protease (P6 Glu, P3 Tyr, P2 Phe, and P1 Gln). Indeed,
substitution of TEV substrate P2 Phe or P1 Gln with the
corresponding IL-23 substrate residue (P2 Gly or P1 His) has
been shown to reduce TEV protease activity by more than an
order of magnitude in each case24. Encouragingly, researchers
previously used site-saturation mutagenesis and an elegant yeast
display screen to identify TEV mutants that accept P1 His instead
of the P1 Gln, demonstrating the evolvability of P1 recognition19.
Evolution of TEV variants that cleave the IL-23 peptide. PACE
requires linking the activity of interest to expression of an
essential phage gene (such as gene III) and thus phage survival.
We previously established such a linkage for a range of activities
including RNA polymerase activity, DNA binding, protein
binding, and protein cleavage22, 29–33. To link proteolysis to gene
expression we used a protease-activated RNA polymerase (PA-
RNAP) consisting of T7 RNA polymerase (T7 RNAP) fused
through a protease-cleavable linker to T7 lysozyme, a natural
inhibitor of T7 RNAP (Fig. 1)32. In this study the PA-RNAP is
expressed from the same host-cell AP that places gene III
expression under control of the T7 promoter, while the evolving
protease is expressed from the SP (Supplementary Figs. 1 and 2).
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We veriﬁed that SP expressing TEV protease S219V, a form
that does not self-cleave (hereafter referred to as “wild-type”),
propagate robustly on host cells expressing a PA-RNAP contain-
ing the TEV consensus substrate, ENLYFQS, in the linker
connecting T7 RNAP and T7 lysozyme. In contrast, replacing the
PA-RNAP linker with the target peptide HPLVGHM results in a
failure of phage to propagate and rapid clearance of phage,
consistent with the inability of wild-type TEV protease, or TEV
variants containing a handful of immediately accessible muta-
tions, to cleave the target IL-23 peptide.
We anticipated that successful evolution of TEV protease
variants that cleave the IL-23 target would require multiple
evolutionary stepping stones20, 29–31, 33 to guide evolving gene
populations through points in the ﬁtness landscape that bring
them successively closer to activity on the ﬁnal target substrate.
We designed three evolutionary trajectories such that substrate
changes known to strongly disrupt the activity of wild-type TEV
protease, including P6 His, P2 Gly, and P1 His,24 were introduced
in the earliest stepping stones (Fig. 2). We confronted these
challenging substitutions ﬁrst while the evolving protease
populations had access to variants with wild-type-like levels of
activity, reasoning that the likelihood of success was higher while
proteases had sufﬁcient activity to exchange for altered speciﬁcity
without falling below a minimum activity threshold needed to
survive selection. We introduced these challenging substrate
changes one stepping stone at a time to avoid collapse of the
evolving phage population and to illuminate at each stage how
mutations within TEV protease altered substrate speciﬁcity.
We began all three evolutionary trajectories (Fig. 2) by
introducing the P6 His substitution (HNLYFQS) into the PA-
RNAP and expressing a site-saturation mutagenesis library of
TEV protease from the SP. Using NNK codons, we simulta-
neously randomized three TEV protease residues N171, N176,
and Y178, all of which are proximal to the P6 substrate residue.
This ﬁrst PACE yielded variants with enhanced apparent activity
on the HNLYFQS substrate (Supplementary Fig. 3) and
genotypes were highly enriched for D127A+S135F+N176I, or
I138T+N171D+N176T (Supplementary Table 3). Mutations
N171D and N176T have been previously characterized as
allowing P6 tolerance for uncharged residues such as threonine
and proline15.
Next we pursued two parallel lines of PACE using either
ENLYGQS (trajectories 1 and 2) or HNLYFHS (trajectory 3) as
the second stepping-stone substrate. For trajectories 1 and 2, we
diversiﬁed the population that emerged from PACE on the ﬁrst
stepping stone (HNLYFQS) with NNK codons at all four TEV
protease residues (209, 211, 216, and 218) that line the
hydrophobic pocket that is occupied by the P2 Phe and
performed PACE using host cells expressing ENLYGQS. The
resulting population of TEV mutants is typiﬁed by the mutations
N176I, V209M, W211I, M218F (Supplementary Table 4), which
confer apparent cleavage activity on both HNLYFQS and
ENLYGQS substrates (Supplementary Fig. 4).
In trajectory 3, we used a mixing strategy to access TEV
proteases that could cleave the HNLYFHS stepping-stone double
mutant substrate. Unlike PACE experiments initiated from a site-
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Fig. 1 Overview of protease PACE. A culture of host E. coli continuously dilutes a ﬁxed-volume vessel containing an evolving population of selection phage
(SP) in which essential phage gIII has been replaced by a protease gene. These host cells contain an arabinose-inducible mutagenesis plasmid (MP) and an
accessory plasmid (AP) that supplies gIII. The expression of gIII is made protease-dependent through the use of a protease-activated RNA polymerase
(PA-RNAP) consisting of T7 RNA polymerase fused through a cleavable substrate linker to T7 lysozyme, a natural inhibitor of T7 RNAP transcription. If an
SP encodes a protease capable of cleaving the substrate linker, then the resulting liberation of T7 RNAP leads to the production of pIII and infectious
progeny phage encoding active proteases. Conversely, SP encoding proteases that cannot cleave the PA-RNAP yield non-infectious progeny phage
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saturation mutagenesis library, a mixing strategy relies on a
transitional period of phage propagation on a mixture of two
different host cell populations, one expressing an accepted
substrate (HNLYFQS) and the other expressing the next
stepping-stone substrate (HNLYFHS). Following this transitional
period, the SP is propagated exclusively on hosts expressing the
next stepping-stone substrate (HNLYFHS). The variants that
emerged from this stage of trajectory 3 showed weak apparent
activity on the double mutant substrate HNLYFHS (Supplemen-
tary Fig. 5), and only a single additional enriched mutation
D148A (Supplementary Table 5). Encouragingly, mutation at
residue D148 has previously been reported to enable activity on
ENLYFHS19.
Due to the low apparent activity of proteases emerging from
this mixing experiment, we relied on the site-saturation
mutagenesis strategy to evolve activity on the third stepping
stone, HNLYGHS. The TEV protease populations from trajectory
3 were randomized at sites implicated in P2 recognition (209, 211,
216, and 218), while for trajectories 1 and 2 the TEV protease
population was simultaneously randomized at four sites (146,
148, 167, and 177) as previously described for the reprogramming
of TEV speciﬁcity at the P1 position19 (Fig. 2). The primers used
to randomize TEV protease residues 167 and 177 must also
encode the identity of intervening amino acids N171 and N176.
Although the population appeared to converge on N176I
(Supplementary Table 4), we reasoned that it was best to preserve
genetic diversity at N176 by constructing one library with primers
encoding N176I (trajectory 1) and another with N171D+N176T
(trajectory 2). Libraries constructed for all three trajectories were
then subjected to PACE on host cells expressing the triple mutant
substrate HNLYGHS. The variants emerging at this stage of
trajectory 1 and 2 were enriched for mutations at residues 146,
148, and 177, consistent with acceptance of the newly introduced
P1 substitution19. Similarly, clones from trajectory 3 exhibit
mutations at residues 209, 211, and 218 that may promote
acceptance of the newly added P2 Gly substitution. Regardless of
trajectory, all clones emerging at this stage exhibit at least one
mutation from each of three targeted mutagenesis libraries
(Supplementary Table 6), suggesting that they have evolved
activity on the triple mutant substrate.
Given the known tolerance of TEV protease for amino acids at
positions P5 and P1ʹ, we speculated that proteases evolved to
recognize the triple mutant substrate HNLYGHS might already
exhibit activity on the ﬁnal target substrate (HPLVGHM). Indeed,
the populations arising from evolution on the triple mutant
substrate successfully propagate in PACE on host cells producing
the HPLVGHM substrate, and the resulting variants display weak
apparent activity on the ﬁnal target substrate (Supplementary
Fig. 6). In order to evolve high levels of activity on the ﬁnal target
substrate from these weakly active mutants, we applied three
strategies to increase selection stringency on all three trajectories:
(1) express a lower concentration of the PA-RNAP substrate by
using a weaker constitutive promoter (proA instead of proB)34;
(2) replace the ﬂexible GGS linker that ﬂanks our substrate with
the native and potentially structured amino sequence from IL-23
(human IL-23 residues 38–66); and (3) introduce a mutation in
the T7 RNAP portion of the PA-RNAP that decreases transcrip-
tional activity (Q649S)35. We conﬁrmed that all three strategies
indeed increased selection stringency (Supplementary Fig. 7).
We ﬁrst applied the lowered substrate concentration strategy
using a mixing experiment to transition from proB to proA
expression of the PA-RNAP; this experiment yielded modest
changes in genotypes. Exploiting the ease of performing PACE on
multiple lagoons in parallel, we implemented the other two
strategies simultaneously on all three trajectories. The resulting
six populations (trajectories 1a, 1b, 2a, 2b, 3a, and 3b; see Fig. 2)
were carried forward into PACE on hosts expressing a PA-RNAP
with both the IL-23 (38–66) linker and the attenuated T7 RNAP
mutant Q649S. In the ﬁnal stage of PACE for all six populations,
we used a proA promoter to generate less of the PA-RNAP
containing the IL-23 (38–66) linker and the Q649S mutation.
This series of stringency modulation experiments produced
variants with higher levels of apparent activity on the ﬁnal
HPLVGHM substrate (Supplementary Fig. 8).
Characterization of evolved TEV protease variants. Mutations
that arise early in long evolutionary trajectories can create a
cascade of contingencies because subsequent mutations must be
compatible with the preexisting genetic context, a phenomenon
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Fig. 2 PACE evolutionary trajectories. Across the eight stages of PACE along three diverging trajectories (shown in purple, blue, and orange), each arrow
represents a PACE experiment with the corresponding substrate peptide and selection stringency parameters listed beneath the arrow. Increased selection
stringency annotations are: Q649S (a T7 RNAP mutant with decreased transcriptional activity), proA (lower expression of substrate PA-RNAP), and IL-23
(38–66) (native IL-23 sequence in place of GGS linker). Numbers above the arrows denote TEV protease residues that were targeted in site-saturation
mutagenesis libraries used to initiate that PACE experiment. In the ﬁrst PACE experiment, wild-type TEV protease was mutagenized at the positions
shown. All other libraries were generated using the protease genes emerging from the previous PACE stage as the PCR template. For PACE stages with no
targeted mutagenesis, lagoons were inoculated with an aliquot of the phage population from the preceding experiment
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known as epistasis. Genotypes suggest that epistasis strongly
shaped the outcomes of trajectories 1 and 2, which were domi-
nated by N176I vs. N171D+N176T, respectively, prior to the
third stage of PACE. During subsequent evolution, the amino
acid identity at amino acid 176 appears to have dictated the
optimal identity of residue 177, such that the combinations N176I
+N177S, or N176T+N177M, predominate trajectories 1 and 2
respectively. Swapping the identity of N177 between clones
from trajectories 1 and 2 results in a substantial loss of activity
(Supplementary Fig. 9), further consistent with epistasis at this
position. It is likely that these genetic differences between tra-
jectory 1 and 2 also later led to the enrichment of distinct
mutations outside of the substrate-binding site (Supplementary
Tables 3–11). For example, mutations at position 203 persisted
only in trajectory 1, while mutations at positions 28, 30, 68, 132,
and 162 were only abundant in trajectory 2.
Unsurprisingly, we observed a dramatically different outcome
in the third trajectory, which not only experienced a different
schedule of stepping-stone substrates but was also subjected to a
mixing experiment instead of NNK mutagenesis at residues 146,
148, 167, and 177. Our data are consistent with a model in which
a lack of diversiﬁcation at these critical residues traps trajectory 3
in a local ﬁtness maximum, evidenced by weak apparent activity
on the ﬁnal target substrate (Supplementary Figs. 6 and 8) and
few genotypic changes after the ﬁfth stage of trajectory 3
(Table 1). Consequently, while all six populations yielded TEV
variants with apparent activity on the ﬁnal target, the TEV
protease variants that exhibited the highest apparent activity on
the ﬁnal target were all derived from trajectories 1 and 2.
Three representative proteases from the end of trajectories 1
and 2 were puriﬁed and assayed in vitro for their ability to cleave
a model protein substrate in which MBP and GST were fused
through a linker containing the ﬁnal HPLVGHM substrate
sequence (Supplementary Fig. 10). All three evolved proteases
cleaved the model substrate. We selected the most active clone
(TEV L2F from trajectory 2, containing 20 non-silent mutations,
Supplementary Table 11) for detailed characterization. We
assayed the kinetic parameters of this mutant enzyme on wild-
type (ENLYFQS) and target (HPLVGHM) substrate peptides
using a previously described HPLC method19. Unlike the wild-
type enzyme, which exhibits no detectable activity on the
HPLVGHM peptide, the L2F variant processes this substrate
with ∼15% of the catalytic efﬁciency (kcat/KM) with which TEV
protease cleaves its native substrate (Table 2 and Supplementary
Fig. 11). Compared to wild-type TEV, evolved TEV L2F appears
to have slightly improved kinetics on the canonical ENLYFQS
substrate, possibly due to broadly activating mutations that
increase kcat, while experiencing only a modest ﬁvefold increased
Km on the target substrate HPLVGHM. These results collectively
indicate that PACE generated a mutant protease that cleaves a
target substrate containing mutations at six positions with only
modestly lower efﬁciency than wild-type TEV protease cleaves its
consensus substrate.
Substrate speciﬁcity proﬁling of an evolved TEV protease.
Proteolysis assays on individual substrates reveal that evolved
TEV protease L2F maintains the ability to detectably cleave
starting and intermediate substrates while acquiring activity on
the ﬁnal IL-23 target (Supplementary Fig. 12). A more compre-
hensive understanding of the substrate speciﬁcity of this evolved
enzyme requires an unbiased protease speciﬁcity proﬁle generated
from a large number of substrate variants. To obtain such a
proﬁle, we applied a previously reported phage substrate display
method (Fig. 3a)36–38. M13 bacteriophage encoding pIII fused to
a FLAG-tag through a library of substrate linkers were immobi-
lized on anti-FLAG magnetic beads. When incubated with a
protease of interest, phage encoding cleaved substrates are liber-
ated from the solid support, while phage encoding the intact
substrates remain immobilized and are eluted with excess FLAG
peptide. The abundance of each substrate in the cleaved and
eluted populations was measured by high-throughput DNA
sequencing, yielding enrichment values (Supplementary Table 12)
and sequence logos (Fig. 3b–e) that convey protease substrate
speciﬁcity across all possible amino acids39.
We applied this speciﬁcity proﬁling technique to seven separate
libraries, each containing a single randomized position within
the canonical ENLYFQS substrate. These libraries are inherently
biased by the identities of the residues that are held constant,
but because of their small theoretical diversity, they are easy to
construct and a single round of selection yielded robust
enrichment values. We validated this method by enrichment
of the consensus motif EXLYFQS (where X= any amino acid)
for wild-type TEV protease (Fig. 3b). We also applied this
substrate speciﬁcity proﬁling method to more complex libraries
containing sets of three consecutive randomized amino acids
within either the ENLYFQS or HPLVGHM substrate. The
resulting speciﬁcity proﬁles from these larger libraries (Supple-
mentary Fig. 13) did not substantially differ from the results of
Table 1 Representative evolved TEV protease genotypes
Trajectory 1
1 D127A S135F N176I
2 D127A S135F N176I V209M W211I M218F
3 D127A S135F T146A D148P N176I N177R V209M W211I M218F
4 D127A S135F T146A D148P N176I N177R V209M W211I M218F K229E
5 E2K D127A S135F T146C D148P S170A N176I N177S R203Q V209M W211I M218F Q226stop
6 E2K D127A S135F T146C D148P S170A N176I N177S R203Q V209M W211I M218F Q226stop
7 E2K D127A S135F T146C D148P S170A N176I N177S R203Q V209M W211I M218F Q226stop
8 E2K D127A S135F T146C D148P S170A N176I N177S R203Q V209M W211I M218F Q226stop
Trajectory 2
1 I138T N171D N176T
2 D127A S135F N171D N176T V209M W211I M218F
3 D127A S135F T146S D148P N171D N176T N177M V209M W211I M218F K229E
4 D127A S135F T146S D148P F162S N171D N176T N177M V209M W211I M218F K229E
5 D127A S135F T146S D148P F162S N171D N176T N177M V209M W211I M218F K229E
6 R50G E107D D127A S135F T146S D148P F162S S170A N171D N176T N177M V209M W211I M218F K229E
7 T30A D127A S135F T146S D148P F162A S170A N171D N176T N177M V209M W211V K215E M218F K229E
8 T17S H28L T30A N68D E107D D127A F132L S135F T146C D148P S153N F162S S170A N171D N176T N177M V209M W211I M218F K229E
Trajectory 3
1 D127A S135F N176I
2 D127A S135F D148A N176I
3 E107D D127A S135F T146A D148A N176I V209E W211L V216I M218W
4 E107D D127A S135F T146A D148A N176I V209F W211C M218L
5 H28Y E107D D127A S135F T146A D148A S153N N176I V209F W211C M218L Q226S P227A V228S K229stop
6 H28Y E107D D127A S135F T146A D148A S153N N176I V209F W211C M218L Q226S P227A V228S K229stop
7 H28Y T30A E107D D127A S135F T146A D148A S153N N176I V209F W211C K215E M218L Q226P P227A V228S K229stop
8 H28Y E107D D127A S135F T146A D148A S153N N176I V209F W211C K215E M218L Q226P P227A V228S K229stop
For each stage of each PACE trajectory, a representative evolved protease clone emerging at the end of the stage (numbered in the ﬁrst column) is shown. The mutations within each clone are listed as
an individual row, illustrating the enrichment of new mutations during successive stages of PACE as well as genotypic differences between trajectories. The enriched stop codon mutations truncate 8 or
11 amino acids of the C-terminus of the protein and preserve proteolytic activity
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the single-site libraries. However, the identity of the constant
residues (ENLYFQS vs. HPLVGHM) did alter the resulting
speciﬁcity proﬁles of TEV L2F; the speciﬁcity of TEV L2F is more
pronounced for P1 His, the target residue, and P6 Glu, the wild-
type residue, in the context of HPLVGHM libraries
(Supplementary Fig. 13 and corresponding enrichment values
in Supplementary Table 13).
When we compare the speciﬁcity proﬁle of evolved TEV L2F
(Fig. 3c) to that of wild-type TEV, a number of differences are
apparent: TEV L2F shows a shifting of P3 speciﬁcity towards
Table 2 Kinetic parameters of wild-type and evolved TEV proteases
Substrate Protease kcat (s−1) Km (μM) kcat/Km (s μM)−1
ENLYFQS Wild-type 0.23± 0.011 170± 22 1.3 × 10−3
HPLVGHM Wild-type ND ND ND
ENLYFQS TEV L2F 0.27± 0.019 150± 28 1.7 × 10−3
HPLVGHM TEV L2F 0.19± 0.010 920± 110 2.0 × 10-4
ND= not detected (no product formation observed after 30min of incubation of 1 μM protease and 2mM substrate with a limit of detection of 1 nM product)
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Fig. 3 Protease speciﬁcity proﬁling. a Overview of phage substrate display. M13 bacteriophage libraries encode pIII fused to a FLAG-tag through a
randomized protease substrate linker. These substrate phage are bound to anti-FLAG magnetic beads and treated with a protease to release phage that
encode substrates that can be cleaved by the protease. The remaining intact substrate phage are eluted with excess FLAG peptide. The abundance of all
substrate sequences within the cleaved and eluted samples is measured by high-throughput sequencing. b–e For all assayed proteases, phage substrate
display was separately performed on seven libraries, each with a different single randomized position within the ENLYFQS motif. The results are displayed
as sequence logos, with letter height proportional to enrichment in the cleaved versus eluted sample. Letters placed above the x-axis indicate protease
acceptance and letters beneath the axis indicate rejection. b Wild-type TEV protease exhibits strong enrichment for the consensus motif EXLYFQS.
c Evolved TEV L2F has broadened speciﬁcity at P6 and shifted speciﬁcity at P3, P1, and P1ʹ in accordance with the HPLVGHM target substrate. dMutations
I138T, N171D, and N176T are sufﬁcient to broaden P6 speciﬁcity. e Mutations T146S, D148P, S153N, S170A, and N177M shift speciﬁcity at both P1 and P3
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aliphatic residues Ile and Val, a shifting of P1 speciﬁcity towards
His, a shifting of P1’ speciﬁcity towards aliphatic amino acids Ala,
Ile, and Met, and a broadening of speciﬁcity at P6. These changes
are consistent with evolutionary pressure to cleave the target
substrate HPLVGHM. Although the evolved L2F protease
recognizes a shortened motif due to loss of P6 speciﬁcity, it
retains the ability to reject the substantial majority of amino acids
at each of the ﬁve others positions used by TEV. The overall
speciﬁcity of the evolved L2F protease lies well within the range of
speciﬁcities exhibited by natural proteases such as caspases,
granzymes, clotting factors, and MMPs, which typically specify
strongly only one or two positions and accept mixtures of several
to many amino acids at other positions, yet retain sufﬁcient
overall speciﬁcity to mediate physiological signaling roles40–43.
Nonetheless, the use of evolved proteases in complex biological
environments may require a proteome-wide evaluation of off-
target substrates to identify potential undesired effects.
Functionally independent groups of TEV mutations. To illu-
minate the molecular basis of the evolved changes in substrate
speciﬁcity, we generated TEV mutants containing small subsets of
mutations and proﬁled their substrate speciﬁcities using substrate
libraries in which a single residue of the ENLYFQS substrate was
randomized. A number of mutations were predicted to inﬂuence
solubility and stability based on previous reports44–46 or their
distance from the substrate in the crystal structure25. We con-
structed various combinations of the predicted solubility muta-
tions (T17S, N68D, E107D, D127A, F132L, S135F, F162S, R203Q,
K215E, and K229E) as well as mutants that putatively inﬂuence
speciﬁcity at P1 (T146S, D148P, S153N, S170A, and N177M), P6
(I138T, N171D, and N176T), and P2 (V209M, W211I, and
M218F) based on the emergence of these mutations during
PACE.
All of the tested combinations of mutations resulted in
proteases that retained activity to varying degrees (Supplementary
Fig. 14), despite being taken out of their PACE-evolved contexts.
As expected, the solubility-enhancing mutants exhibited no
signiﬁcant change in speciﬁcity (Supplementary Fig. 15). The
P2 variant also did not display any substantial speciﬁcity changes,
consistent with the lack of a strong change in P2 speciﬁcity in the
TEV L2F speciﬁcity proﬁle (Supplementary Fig. 15).
Mutations in the P6 variant (I138T, N171D, N176T) are
sufﬁcient to confer loss of glutamate speciﬁcity at P6 with no
other obvious changes to substrate preferences (Fig. 3d),
suggesting some degree of modularity in protease–substrate
interactions. Conversely, the P1 variant (T146S, D148P, S153N,
S170A, and N177M) not only exhibits broadened speciﬁcity at the
P1 site, but also shows a concurrent increased afﬁnity for P3
aliphatic side chains (Fig. 3e). The mutations within these two
variants appear to be responsible for the three largest differences
in substrate speciﬁcity between wild-type TEV and TEV L2F.
Evolved TEV L2F cleaves human IL-23. Next we tested the
ability of the evolved TEV L2F protease to cleave full-length
human IL-23 protein. In its active form, IL-23 is a heterodimer
between the IL-12p40 subunit and the IL-23p19 subunit. We
incubated TEV L2F with IL-23 in either its heterodimeric or
monomeric p19 state, and observed by Western blot the forma-
tion of a single cleavage product for the IL-23 heterodimer, and in
the presence of excess protease, two cleavage products for the
monomeric IL-23p19 substrate (Supplementary Fig. 16).
IL-23 digestion reactions were subjected to LC–MS to identify
the cleavage products. The heterodimer cleavage reaction
generated a single protein product of mass 3598 Da less than
the starting material, matching the fragment liberated by cleavage
of the target peptide bond at the HPLVGH//M sequence
(Supplementary Fig. 17). Data from the monomer cleavage
reaction in the presence of a 1.5-fold excess of TEV L2F revealed
two new product masses corresponding to a single cleavage at the
target site (HPLVGH//M), as well as proteolysis at both the target
site (HPLVGH//M) and an additional secondary site (ARVFAH//
G) that is also consistent with the L2F speciﬁcity proﬁle shown in
Fig. 3c (Supplementary Fig. 18). The absence of an ion
corresponding to IL-23 cleaved at only the secondary site suggests
that the target site is kinetically favored by TEV L2F. The
secondary site was only cleaved in the monomeric substrate and
not the heterodimer presumably because it is occluded by the IL-
12p40 subunit in the heterodimer structure (Supplementary
Fig. 19)47.
Evolved TEV deactivates IL-23 and prevents IL-17 secretion.
Finally we tested the ability of the evolved TEV L2F protease to
abrogate the biological activity of IL-23. We used a previously
described IL-23 activity assay with primary isolates of mouse
mononuclear splenocytes48. When cultured in the presence of IL-
2 and IL-23, Th17 cells are stabilized and secrete IL-17 into the
media supernatant, which is quantiﬁed by ELISA. We observed a
dose-dependent attenuation of IL-17 production when IL-23 was
pre-incubated with TEV L2F (Fig. 4). These samples were also
visualized by western blot demonstrating that the p40 subunit is
unaffected by incubation with protease, and that inhibition of IL-
17 production is causally linked to IL-23p19 cleavage (Supple-
mentary Fig. 20). A sub-stoichiometric dose of L2F protease (0.40
equivalents) resulted in the loss of nearly all IL-23-induced IL-17
secretion, consistent with TEV L2F catalyzing cleavage of IL-23
following multiple turnover Michaelis–Menten kinetic behavior
that we observed in previous experiments using synthetic peptide
substrates (Table 2 and Supplementary Figs. 21 and 22). Direct
addition of TEV L2F to splenocyte cultures in serum-containing
media supplemented with IL-23 did not attenuate IL-17 secretion
(Supplementary Fig. 23). The presence of an equivalent con-
centration of serum did not inhibit cleavage in vitro (Supple-
mentary Fig. 24), suggesting that TEV protease activity could be
diminished in the oxidizing cell culture supernatant. Alter-
natively, it is possible the protease is sequestered by other secreted
factors or cell-surface proteins within the complex culture media,
or that IL-23 binding to IL-23R may occur faster than IL-23
proteolysis.
Discussion
The generation of on-demand biochemical catalysts has been a
longstanding interest of the scientiﬁc community49. Previous
efforts to evolve protease speciﬁcity have been successful at
altering the substrate speciﬁcity of model proteases by one or two
amino acids15–20. By using PACE to conduct ∼2500 total gen-
erations of evolution in three diverging evolutionary trajectories,
evolutionary stepping stones to guide populations through long
evolutionary trajectories, and both targeted and elevated random
mutagenesis, we evolved TEV protease variants that cleave a
substrate dramatically different from the wild-type substrate with
only a modest decrease in kinetic parameters compared with
wild-type TEV on its consensus substrate. This work demon-
strates for the ﬁrst time that a protease can be reprogrammed
through laboratory evolution to cleave and deactivate a target
protein containing a very different substrate sequence than is
recognized by the wild-type protease. Our approach also exem-
pliﬁes a target selection strategy that integrates knowledge from
known positional tolerances of a wild-type enzyme with results
from previous evolution efforts. The above data also demonstrate
that evolved L2F protease has sufﬁcient speciﬁcity to avoid
degrading itself, the numerous proteins required for the PACE
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selection, MBP, GST, or essential protein components of the IL-
23 assay beyond IL-23. The ability of the L2F protease to cleave
IL-23 is also not inhibited by the presence of 10% fetal bovine
serum, which contains high concentrations of other proteins. The
speciﬁcity of the evolved L2F protease overall resembles that of
many natural proteases, which like L2F reject the majority of
possible amino acids but accept mixtures of others at each
recognized substrate position40–43.
While these advances suggest the utility of evolved proteases
for many research and industrial applications, they face addi-
tional challenges for therapeutic applications. The evolution of
proteases under many generations of positive selection alone can
result in proteases that accept the target substrate but do not
reject the wild-type or intermediate substrates. In cases in which
it is desirable to reject cleavage of certain non-target substrates,
the application of a PACE negative selection strategy to apply
selection pressure against non-target cleavage may be useful30.
Moreover, any circulating foreign protein therapeutic if admi-
nistered repeatedly poses a substantial immunogenicity risk.
Consequently, ideal starting points for therapeutic protease evo-
lution may be circulating human proteases, such as the use of
human kallikrein 7 in a pioneering study that sculpts its speciﬁ-
city to more selectively proteolyze human amyloid beta50. The
PACE of a human protease will present a signiﬁcant but tractable
technical hurdle, producing enzymes containing disulﬁde bonds
in active forms in the E. coli cytosol51–54.
These challenges notwithstanding, this study represents a
foundation for the directed evolution of proteases with highly
altered speciﬁcities. We demonstrate the feasibility of catalytic
inactivation of a target protein with an evolved protease, which in
some cases may offer substantial beneﬁts over stoichiometric
binding of a neutralizing antibody. In addition to potency
advantages, we anticipate that evolved proteases may also enable
research and therapeutic applications that are unavailable to
antibodies such as proteolysis-induced gain-of-function and
proteolysis-mediated alteration of a protein’s import, export,
subcellular localization, half-life, or post-translational modiﬁca-
tion state.
Methods
Ranking of target sites within extracellular proteins. A list of human extra-
cellular and transmembrane proteins with their corresponding amino acid
sequences were tabulated using the ProteinData functionality in Mathematica 10.
This data was transferred into MATLAB for further processing by a customizable
script that performed the following operations (Supplementary Note 1). A rating
matrix that is seven positions wide (for the seven sites within the TEV protease
recognition motif) by 20 long (for each possible amino acid) was manually
populated with subjective “evolvability” integer ratings. Each protein was converted
into a binary sparse matrix with as many rows as the length of the protein sequence
and 20 columns one for each amino acid. For each protein matrix, seven rows at a
time were multiplied by the “evolvability” matrix, with the trace of the resulting 7 ×
7 product matrix providing a score for the heptapeptide. For each extracellular
protein the best score and the corresponding peptide and starting-residue index
were saved. Once all protein sequences had been processed, we sorted the protein
names along with their best-match candidate substrate sequences by score.
Expression vectors and phage libraries. All primers were designed to perform
USER cloning55 and ordered from Integrated DNA Technologies (IDT). For the
cloning of phage libraries, NNK codons were generating using hand-mixed
phosphoramidite ratios to provide uniform incorporation rates (Supplementary
Table 15). All PCR reactions were performed using Phusion U Hot Start poly-
merase (Thermo-Fisher).
For the assembly of APs and expression vectors, PCR products were puriﬁed
using EconoSpin columns (Epoch Life Sciences) and assembled with DpnI and
USER enzyme in CutSmart Buffer (New England BioLabs). Following assembly,
plasmids were transformed into NEB Turbo Competent E. coli cells (New England
BioLabs).
For the assembly of phage libraries, PCR products were puriﬁed by gel
electrophoresis and extracted using the MinElute kit by Qiagen. Following an
assembly reaction identical to that of the AP, the USER reaction was desalted using
the MinElute PCR puriﬁcation kit (Qiagen) prior to electroporation into competent
E. coli S105922 (for SP libraries) or NEB Turbo Electrocompetent E. coli cells22 (for
substrate display phage libraries). Phage libraries were grown overnight in 2×YT
and ﬁltered through sterile 0.22 μmmembranes to eliminate host cells. The titers of
phage libraries were evaluated by plaque assay using strain S1059 as hosts. Brieﬂy,
phage were prepared in four 50-fold serial dilutions of 50 µl. To each dilution was
added 100 µl of fresh host cell culture at approximately OD600= 1.0 followed by
addition of 900 µl top agar (2×YT, 6 g L−1 agar). The mixture was mixed by pipet,
then transferred to a quarter-plate prepared with a thin layer of bottom agar
(2×YT, 16 g L−1 agar). Plaque assays were incubated overnight at 37 °C.
In order to assess library quality, 12 clones were sequenced to conﬁrm diversity
at the targeted amino acid positions. Brieﬂy, individual plaques were picked with a
pipet tip in order to provide template material (SP-infected E. coli) for rolling circle
ampliﬁcation (TempliPhi, GE Healthcare). Sanger DNA sequencing was performed
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Fig. 4 Protease-mediated attenuation of IL-17 secretion in mouse splenocytes. The activity of IL-23 in vivo is mediated by stabilization of a T-helper cell
lineage (Th17) that secretes IL-17, leading to downstream pro-inﬂammatory signals. This pathway can be assayed within a culture of mouse mononuclear
splenocytes, by measuring the amount of IL-17 secretion into the cell culture media using an ELISA. As a positive control, anti-IL-23 antibodies in a super-
stoichiometric ratio prevent IL-17 secretion. Preincubation of IL-23 and evolved TEV L2F attenuates IL-17 secretion, demonstrating that cleavage of the
HPLVGHM target site inactivates immune signaling capabilities of IL-23. Values represent the mean and error bars represent the standard deviation of
three technical replicates
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using primer BCD1136 (Supplementary Table 15), and results were aligned and
tabulated using SeqMan (DNAStar).
PACE experiments. PACE experiments were performed as follows: 22, 29–33.
Brieﬂy, E. coli strain S1030 was co-transformed by electroporation with a muta-
genesis plasmid (MP6)23 and an AP (plasmids are described in Supplementary
Table 14 and detailed in Supplementary Figs. 1 and 2). Chemostats containing
80 ml of Davis Rich Media with 22.5 μg ml−1 carbenicillin and 15 μg ml−1 chlor-
amphenicol were inoculated with overnight starter cultures and grown at 37 °C
while mixing at 250 rpm via a magnetic stir bar. Once the chemostat grew to
∼OD600= 1.0, we began dilution with fresh media at a rate of 80–100 ml h−1, with
the waste needle set at a height of 80 ml. At the same time, we began the ﬂow of
chemostat culture at ∼10–20 ml h−1 into a lagoon with a waste needle set at a
height of 15 ml. The total ﬂow rate through each lagoon was set based upon the
difﬁculty of a given experiment, with slower dilution being used for more chal-
lenging evolutions. For the full duration of the experiment 10% w/v arabinose
solution was syringe-pumped into the lagoons at a rate of 0.5–1.0 ml h−1.
Experiments starting with an NNK mutagenized SP library initiated with a
lagoon inoculum of 1–2 ml of phage library containing 108–1010 pfu ml−1. For all
other experiments, lagoons were inoculated with 50–100 μl of ﬁltered phage
population from the last time point of the previous PACE experiment. In PACE
experiments using mixtures of host cell cultures (see the main text), lagoons
received an inﬂux of cell culture from two separate chemostats containing hosts
bearing two different APs (combined rate of 10–20 ml h−1) for a period of 24–48 h.
Phage samples were collected from lagoon waste outﬂow lines at 24 h intervals
and passed through a 0.22 µm sterile ﬁlter to remove host cells. The titers of phage
samples were evaluated by plaque assay using strain S1059 as hosts. At the end of
each PACE experiment, eight individual plaques were picked with a pipet tip in
order to provide template material (SP-infected E. coli) for rolling circle
ampliﬁcation (TempliPhi, GE Healthcare). The same pipet tip was subsequently
transferred to a 96-deep well culture plate containing 2×YT media for growth
overnight at 37 °C. After a PACE experiment, enriched mutations should be
present within multiple clones of this small sample of eight population members.
Sanger DNA sequencing was performed using primer BCD1136 (Supplementary
Table 15), and results were aligned and tabulated using SeqMan (DNAStar).
Luminescence assays of evolved clones. Clones chosen for characterization were
sterile-ﬁltered from the corresponding position within the 96-well culture plate.
Saturated overnight cultures of S1030 cells containing a substrate AP were used to
initiate luciferase assays in 96-well culture plates. Approximate volumes were 500 µl
2×YT, 50 µl overnight starter culture, and 10 µl ﬁltered phage samples. All assays
included a negative control (no phage), a positive control (SP encoding T7 RNAP),
and wild-type TEV SP as a reference. Experimental and control conditions were
performed in triplicate. After 3–5 h of growth in a 37 °C shaker, 100 µl was
transferred to a clear-bottom assay plate to measure OD600 and luminescence on a
Tecan Inﬁnite Pro Plate Reader. Measurements were analyzed as OD-normalized
values and as luminescence fold-change over the negative control.
Puriﬁcation of TEV proteases and fusion protein substrates. TEV protease was
puriﬁed as previously described19, 44–46, but with minor modiﬁcations. Brieﬂy,
OneShot BL21 Star (DE3) chemically competent cells (Invitrogen) were trans-
formed with expression vectors encoding MBP fused through a TEV cleavage site
to a 6×His-tagged TEV protease. A total of 5 ml of saturated overnight starter
culture was added to 1–2 l of LB+kanamycin (40 µg ml−1), and grown at 37 °C until
OD600= ~0.7. Expression was induced with 1 mM IPTG for 4 h at 30 °C, and cells
were harvested by centrifugation at 6000 × g for 5 min. The pellet was resuspended
in 15–25 ml binding buffer (10% glycerol, 50 mM Tris pH 8.0, 1.0 M NaCl, 1 mM
DTT, and 20 mM imidazole) with a Roche Complete EDTA-free protease inhibitor
tablet (note that TEV protease is unaffected by conventional protease inhibitors).
Cells were lysed by sonication for 4 min with a 1-s on, 1-s off cycle at medium
power. Lysate was clariﬁed by centrifugation at 18,000 × g for 20 min. Clariﬁed
lysate was incubated with 1–2 ml TALON metal afﬁnity resin (Clontech) for 1 h
mixing end-over-end at 4 °C. Resin was pelleted at 700 × g for 5 min, and resus-
pended with 10 ml of binding buffer to load onto a gravity ﬂow column. Resin was
washed with 10 column volumes of binding buffer, followed by 2 column volumes
of bind buffer with imidazole supplemented to 50 mM. TEV protease was eluted
with 4 column volumes of elution buffer (10% glycerol, 50 mM Tris pH 8.0, 0.1 M
NaCl, 1 mM DTT, and 250 mM imidazole). The purity of fractions was assessed by
SDS-PAGE using precast Bolt 4–12% Bis–Tris gels (ThermoFisher), and TEV
containing fractions were pooled and concentrated to <250 µl using an Amicon
Ultra Centrifugal ﬁlter with a 10 kDa molecular weight cut-off (EMD-Millipore).
The concentrated sample was further puriﬁed to >95% using a SuperDex 200
Increase 10/300 column (GE Healthcare) running with storage buffer (20% gly-
cerol, 50 mM Tris pH 8.0, 0.1 M NaCl, 1 mM DTT). Proteases used in mammalian
cell culture were further subjected to endotoxin removal resin (Pierce), followed by
assaying with an LAL endotoxin quantiﬁcation kit (Pierce). Protein concentrations
were determined by Bradford Assay (ThermoFisher) and aliquots were frozen in
liquid nitrogen for storage at −80 °C.
MBP–GST test substrates were expressed, puriﬁed, and stored exactly as
described above for TEV, except for the following changes. Expression was induced
with 1 mM IPTG for 16 h at 20 °C, and binding buffer was 50 mM Tris pH 8.0,
0.5 M NaCl, supplemented with a Roche Complete EDTA-free protease inhibitor
tablet. After sonication and centrifugation, clariﬁed lysate was incubated with 1 ml
glutathione-linked sepharose (Clontech) for 1 h mixing end-over-end at 4 °C.
Loaded resin was washed with 40 column volumes of binding buffer, followed by 4
column volumes of elution buffer (50 mM Tris pH 8.0, 100 mM NaCl, 10 mM
glutathione). Samples were >95% pure as assessed by SDS-PAGE and were
dialyzed against storage buffer (20% glycerol, 50 mM Tris pH 8.0, 0.1 M NaCl,
1 mM DTT) using Slide-A-Lyzer Cassettes with a 10-kDa molecular weight cut-off
(ThermoFisher).
Assaying proteolysis of fusion protein substrates. Protease assays consisted of
5 µg of MBP–GST substrate and 1 µg of wild-type or evolved TEV protease
incubated for 3 h at 30 °C in storage buffer (20% glycerol, 50 mM Tris pH 8.0,
0.1 M NaCl, 1 mM DTT) supplemented with freshly prepared DTT to a ﬁnal
concentration of 2 mM. Reactions were analyzed by SDS-PAGE and visualized with
Coomassie stain.
HPLC kinetics assay. Protease kinetics were determined as previously described19,
but with minor adjustments. Brieﬂy, synthetic peptide substrates
(THPLVGHMGTRRW-dinitrophenol-lysine and TENLYFQSGTRRW-dini-
trophenol-lysine) and synthetic standards for cleaved products (MGTRRW-dini-
trophenol-lysine and SGTRRW-dinitrophenol-lysine) were ordered from
Genscript. Dinitrophenol moieities provided strong absorbance at 355 nm for more
accurate quantiﬁcation. Reactions and standards were analyzed by HPLC on a C18
reverse-phase column (Kinetex 5μ C18 100A, Phenomenex) using an acetonitrile
gradient from 5 to 50%. Standard curves were constructed for both products
(MGTRRW-dinitrophenol-lysine and SGTRRW-dinitrophenol-lysine) to enable
quantiﬁcation of reaction progress.
Reactions were carried out with 0.05–0.1 μM protease and 50 μM to 2 mM
substrate. Proteases (in storage buffer plus 1 mM freshly prepared DTT) and
substrates (in sterile water) were prepared as solutions at 2× concentration (50 µl
each) then combined to yield a total reaction volume of 100 µl. Reactions were
incubated at 30 °C for 10 min and quenched with 25 µl of 5% TFA. After
quenching, protease was eliminated from samples using an Amicon Ultra
Centrifugal ﬁlter with a 10-kDa cut-off (EMD-Millipore). Prior to conducting
reactions in triplicate, all conditions were tested and monitored at 5, 10, 30 min to
ensure that 10 min was within the linear range of the reaction (<25% substrate
consumption). Peak integrations were tabulated, converted into product
concentrations using the standard curves, and ﬁt to the Michaelis–Menten kinetics
model using Prism GraphPad.
Protease speciﬁcity proﬁling. For each combination of library and protease, 60 µl
of a 50% suspension of Anti-FLAG M2 Magnetic beads (Sigma) was transferred
into a 1.5-ml eppendorf tube. For all subsequent manipulations, a magnetic plate
was used to separate beads and allow aspiration of the supernatant. After washing
with 1 ml of TBS (20 mM Tris pH 7.0, 150 mM NaCl), beads were incubated with
30–100 µl of substrate phage libraries (titers ranged from 108 to 1010 pfu ml−1) in
1 ml of TBS at room temperature for 2 h rotating end-over-end. After initial
binding, the supernatant was discarded and beads were washed with 1 ml of TBS.
Beads with bound substrate phage were incubated in 0.5 ml TBS containing 0.5 µM
protease for 2 h. Supernatant containing cleaved substrate phage was recovered,
and the beads were again washed with 1 ml of TBS. The remaining bound
uncleaved substrate phage was eluted in 0.1 ml of TBS containing 0.1 mg ml−1
FLAG peptide (Sigma).
For substrate libraries containing a single randomized amino acid position, a
single round of selection was sufﬁcient. For substrate libraries containing windows
of three randomized amino acids, a second round of selection was necessary to
detect enrichment. In these cases, the round 1 cleaved substrate phage were
expanded in overnight cultures consisting of 100 µl cleaved substrate phage and
900 µl S1030 culture (diluted to OD600= ~0.1). Following outgrowth, cultures were
centrifuged to pellet E. coli prior to aspirating the supernatant phage to be used in a
second round of phage substrate display as previously described. Due to expansion
biases during outgrowth, these speciﬁcity proﬁles were only interpreted after
normalizing to the second round elution of the no-protease control experiments.
High-throughput sequencing and data analysis. Samples were ampliﬁed by PCR
using Q5 Hot Start 2× Master Mix (NEB) with 1 µl of template phage sample and
primers (MSP819 or MSP820, and MSP824, see Supplementary Table 15). Illumina
barcodes were added in a second PCR reaction using 1 µl of the ﬁrst round PCR
material as template. Samples were pooled and puriﬁed by gel electrophoresis using
a MinElute Gel Extraction kit (Qiagen). The concentration of the pooled library
was measured by Quant-iT PicoGreen dsDNA Assay (ThermoFisher) and diluted
to ∼4 nM. This concentration was further adjusted based on qPCR quantiﬁcation
(Kapa Biosystems). Samples were loaded onto an Illumina MiSeq using a v2 50-
cycle kit set up to run a single-direction read of 50 nucleotides.
Data was automatically demultiplexed by MiSeq Reporter software and the
resulting fastq ﬁles were processed by a custom Python script (Supplementary
Note 2). This script searches each sequencing read for a perfect match to sequences
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ﬂanking both sides of the proteolysis site. If the proteolysis site in between these
matching ﬂanks is exactly 21 nucleotides, then the proteolysis site is translated to a
seven amino acid sequence. Sequences were disregarded in subsequent analysis if
they contained a stop codon, were template material used in library cloning
(HNLYGHS), or were the FLAG tag sequence (YKDDDDK) due to spontaneous
genetic deletion of the proteolysis site. The list of proteolysis sites was tabulated
into a position-speciﬁc amino acid frequency table. For each library-protease
combination, enrichment values were calculated as freqcleaved/freqelution-1. For each
protease, speciﬁcity data from the randomized position within single-site libraries
was combined into a single table and converted into a sequence logo using a the
Seq2Logo webserver39. For libraries containing windows of three randomized
positions, sequence logos for each protease-library combination were separately
generated.
Western blot visualization of recombinant IL-23 cleavage. IL-23 was purchased
as a Myc-tagged IL-23p19 monomer (TP309680 Origene) and as a heterodimer of
IL-23p19 and IL12p40 (PHC9321 ThermoFisher). A total of 5 µg of heterodimer or
0.44 µg of monomer was incubated with 5 µg of TEV L2F for 3 h at 30 °C in storage
buffer (20% glycerol, 50 mM Tris pH 8.0, 0.1 M NaCl, 1 mM DTT) supplemented
with freshly prepared DTT to a ﬁnal concentration of 2 mM. Samples were elec-
trophoresed on precast Bolt 4–12% Bis–Tris gels (ThermoFisher), then transferred
to a PVDF membrane using the iBlot 2 Dry Blotting System (ThermoFisher).
Membranes were incubated at room temperature for 30 min in Odyssey Blocking
Buffer (LiCor). Primary antibody (IL-23 Antibody (26H20L23), ABﬁnity Rabbit
Monoclonal, ThermoFisher) was added to blocking buffer in 1:1000 dilution, and
the membrane was incubated on a rocker at 4 °C overnight. After three washes with
TBST (20 mM Tris pH 7.0, 150 mM NaCl, 0.1% Tween 20), the membrane was
incubated 1 h at room temperature in blocking buffer containing a 1:1000 dilution
secondary antibody (IRDye 800CW Donkey anti-Rabbit IgG, LiCor). After three
more washes with TBST, the membrane was scanned using an Odyssey Imaging
System.
LC–MS identiﬁcation of cleavage sites. IL-23p19 and the IL-23 heterodimer
(ThermoFisher) were reduced with 10 mM DTT to identify intact masses of
unreacted IL-23p19 subunits. IL-23 substrates were incubated in a manner similar
to western blots for 3 h at 30 °C using 2–10 µg of substrate and 4 µg of TEV L2F. All
samples were analyzed using an Agilent LC–MS 6220 (ESI-TOF) equipped with an
Agilent PLRP-S column. A standard protein LC method was used containing a 15-
min reverse-phase gradient (0.1% formic acid in water, MeCN 0.1% formic acid).
IL-23-induced IL-17 production in mouse splenocytes. The following protocol
was adapted from previous work48 as follows: two male mice (C57BL/6J) were
euthanized and dissected to isolate spleens, under a protocol approved by the
Broad Institute Institutional Animal Care and Use Committee. Spleens were pul-
verized into 10 ml of cell culture media (DMEM, Glutamax, high-glucose, peni-
cillin, streptomycin, 10% Fetal Bovine Serum, FBS, ThermoFisher) through a 100
µm nylon mesh Falcon Cell Strainer (Corning). Cell suspensions were centrifuged
for 3 min at 700 g, and the supernatant was discarded. The pellet was resuspended
in 1 ml ACK lysis buffer (Gibco/ThermoFisher). After 5 min, lysis was stopped
with the addition of 9 ml of DMEM, and cells were pelleted by centrifugation at
700 × g for 3 min. If the pellet was red due to remaining red blood cells, ACK lysis
was repeated. Otherwise if the pellet was white, lysis was complete and cells were
resuspended in 4 ml of DMEM. Cell density was quantiﬁed using a Scepter 2.0
Handheld Automated Cell Counter (Millipore). Cultures were diluted to 2 × 106
cells per ml in cell culture media supplemented with 100 units per ml recombinant
human IL-2 (Roche). The outer perimeter wells of a 96-well round bottom culture
plate were ﬁlled with 100 µl of cell-free media to prevent evaporative loss in central
wells containing cell cultures. The central wells were prepared in triplicate ﬁlled
ﬁrst with 125 µl of culture followed by 25 µl of additives (see below). Cell culture
supernatant was sampled after two days of growth, and 10 µl was used to perform a
mouse IL-17 ELISA (R&D Systems).
Additives containing IL-23 and varying doses of protease or neutralizing
antibody (MAB1510, R&D Systems) were prepared in cell culture media
immediately prior to mixing with splenocytes. Additives containing doses of
proteases were also prepared as pre-incubated samples at 300× ﬁnal concentration.
Incubation was performed at 4 °C for 16 h in storage buffer (20% glycerol, 50 mM
Tris pH 8.0, 0.1 M NaCl, 1 mM DTT) supplemented with 2.5 mg ml−1 of BSA
carrier-protein to enhance stability during incubation. These pre-incubated
samples were prepared at high concentration to conﬁrm cleavage efﬁciency by
western blot as described above. However, this western blot was conducted using
two primary antibodies Anti-IL-12p40 (ab62822 Abcam)/Anti-IL-23p19 (sc271279
Santa Cruz) (dilutions were 1:500 and 1:100 respectively) and two secondary
antibodies IRDye800CW Donkey anti-Mouse/IRDye 680RD Donkey anti-Goat
(LiCor) (dilutions were 1:2000 each).
Data availability. High-throughput sequencing data will be made available via the
Sequence Read Archive under BioProject number PRJNA397152. DNA sequences
and constructs are available from Addgene. Complete mutational tables are pro-
vided in Supplementary Information.
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